Bioequivalence study of fixed-dose combination Losartan + amlodipine + rosuvastatin Sanofi in comparison with coadministered fixed- dose combination Lozap® AM and monocomponent drug Crestor® in healthy subjects

• Hoofdauteurs: A. L. Khokhlov (Auteur), D. Yu. Grebenkin (Auteur), E. K. Faeva (Auteur), V. I. Kazey (Auteur), A. A. Khokhlov (Auteur), A. E. Miroshnikov (Auteur), O. V. Lebedeva (Auteur)
• Formaat: Boek
• Gepubliceerd in: LLC "Publisher OKI", 2022-05-01T00:00:00Z.
• Onderwerpen: article
• Online toegang: Connect to this object online.

Introduction. The advantages of fixed-dose combination losartan + amlodipine + rosuvastatin compared to mono-drugs and two-component combinations are to increase the therapeutic efficacy, to reduce the cost of the product and to make the drug easier to take which helps to improve patient adherence t...